Efalizumab (Raptiva ™) is a representative example of a biologic agent, for which two large phase III trials have recently been completed. It is a targeted T-cell modulator that inhibits ...

Fortunately, many recent case reports as well as a recent phase IV study suggest that the biologic agent efalizumab (Raptiva ®) may be effective in treating psoriasis of the hands and/or feet ...